Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
THRX > SEC Filings for THRX > Form 8-K on 13-Jan-2014All Recent SEC Filings

Show all filings for THERAVANCE INC

Form 8-K for THERAVANCE INC


13-Jan-2014

Other Events


Item 8.01 Other Events.

On January 13, 2014, GlaxoSmithKline plc (GSK) and Theravance, Inc. announced the launch of RelvarŽ ElliptaŽ in Germany following the recent approval in Europe in November 2013. RelvarŽ is a fixed dose combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta2-agonist (LABA), vilanterol "VI" (FF/VI). The components will be administered using the ElliptaŽ, a new dry powder inhaler (DPI). In Germany the product is indicated for:

? Asthma: For the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:

o patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta2-agonists.

? COPD: For the symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.

RelvarŽ ElliptaŽ has been developed under the LABA collaboration agreement between Glaxo Group Limited and Theravance, Inc.


  Add THRX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for THRX - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.